NO20082136L - 1,5-substituerte indol-2-yl-amidderivater - Google Patents

1,5-substituerte indol-2-yl-amidderivater

Info

Publication number
NO20082136L
NO20082136L NO20082136A NO20082136A NO20082136L NO 20082136 L NO20082136 L NO 20082136L NO 20082136 A NO20082136 A NO 20082136A NO 20082136 A NO20082136 A NO 20082136A NO 20082136 L NO20082136 L NO 20082136L
Authority
NO
Norway
Prior art keywords
amide derivatives
substituted indol
compounds
indol
substituted
Prior art date
Application number
NO20082136A
Other languages
English (en)
Inventor
Sven Taylor
Olivier Roche
Jean-Marc Plancher
Hans Richter
Matthias Heinrich Nettekoven
Valerie Runtz-Schmitt
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37814240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20082136(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20082136L publication Critical patent/NO20082136L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse angår forbindelser med formel I hvor R1 til R4 og G samt farmasøytisk akseptable salter derav er som definert i beskrivelsen og kravene. Forbindelsene er anvendelige for behandling og/eller forebygging av sykdommer som er forbundet med moduleringen av H3 reseptorer. 1
NO20082136A 2005-11-30 2008-05-07 1,5-substituerte indol-2-yl-amidderivater NO20082136L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05111478 2005-11-30
PCT/EP2006/068655 WO2007062999A2 (en) 2005-11-30 2006-11-20 1,5-substituted indol-2-yl amide derivatives

Publications (1)

Publication Number Publication Date
NO20082136L true NO20082136L (no) 2008-06-30

Family

ID=37814240

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082136A NO20082136L (no) 2005-11-30 2008-05-07 1,5-substituerte indol-2-yl-amidderivater

Country Status (18)

Country Link
US (1) US7745479B2 (no)
EP (1) EP1957479B1 (no)
JP (1) JP4879997B2 (no)
KR (1) KR101124156B1 (no)
CN (1) CN101316840B (no)
AR (1) AR057989A1 (no)
AT (1) ATE500244T1 (no)
AU (1) AU2006319234B2 (no)
BR (1) BRPI0619268A2 (no)
CA (1) CA2630314A1 (no)
DE (1) DE602006020482D1 (no)
ES (1) ES2359739T3 (no)
IL (1) IL191314A (no)
NO (1) NO20082136L (no)
RU (1) RU2008126391A (no)
TW (1) TWI333490B (no)
WO (1) WO2007062999A2 (no)
ZA (1) ZA200804301B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1968967B1 (en) * 2005-11-30 2011-04-27 F. Hoffmann-La Roche AG 1,1-dioxo-thiomorpholinyl indolyl methanone derivatives for use as h3 modulators
ATE466007T1 (de) * 2005-11-30 2010-05-15 Hoffmann La Roche 5-substituierte indol-2-carbonsäureamidderivate
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
US8012955B2 (en) * 2006-12-28 2011-09-06 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
US7507736B2 (en) 2007-02-07 2009-03-24 Hoffmann-La Roche Inc. Indol-2-yl-piperazin-1-yl-methanone derivatives
JP5544296B2 (ja) 2007-11-16 2014-07-09 ライジェル ファーマシューティカルズ， インコーポレイテッド 代謝障害のためのカルボキサミド、スルホンアミド、およびアミン化合物
ES2553340T3 (es) * 2007-12-12 2015-12-07 Rigel Pharmaceuticals, Inc. Compuestos de carboxamida, sulfonamida y amina para trastornos metabólicos
MX2010011288A (es) * 2008-04-23 2010-11-09 Rigel Pharmaceuticals Inc Compuestos de carboxamida para el tratamiento de trastornos metabolicos.
US9394294B2 (en) * 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8765737B1 (en) * 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
MX2013000733A (es) 2010-07-23 2013-05-30 Demerx Inc Composiciones de noribogaina.
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
HUE043171T2 (hu) * 2011-10-07 2019-08-28 Takeda Pharmaceuticals Co Neurodegeneratív betegségek kezelésére hasznos 1-arilkarbonil-4-oxi-piperidinvegyületek
CA2855994A1 (en) 2011-12-09 2013-06-13 Demerx, Inc. Phosphate esters of noribogaine
AU2013212139A1 (en) 2012-01-25 2014-06-26 Demerx, Inc. Synthetic voacangine
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
WO2014098877A1 (en) 2012-12-20 2014-06-26 Demerx, Inc. Substituted noribogaine
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
US9422281B2 (en) 2013-11-18 2016-08-23 Forma Therapeutics, Inc. Benzopiperazine compositions as BET bromodomain inhibitors
WO2015074064A2 (en) 2013-11-18 2015-05-21 Bair Kenneth W Tetrahydroquinoline compositions as bet bromodomain inhibitors
CN105523986A (zh) * 2015-12-30 2016-04-27 江汉大学 一种外排泵抑制剂n-氢-2-芳基吲哚及其衍生物的合成方法
WO2021117353A1 (ja) 2019-12-11 2021-06-17 富士フイルム株式会社 半月板投影面設定装置、方法およびプログラム
CN115340460B (zh) * 2022-09-21 2024-07-16 江西亚太科技发展有限公司 一种Reissert吲哚合成反应中间体的合成方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1328881C (en) * 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA1270837A (en) * 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
US5246960A (en) * 1984-12-21 1993-09-21 Hoffmann-La Roche Inc. Oxetanones
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
CA2340056C (en) 1998-08-14 2007-01-09 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors
PT1105123E (pt) 1998-08-14 2004-08-31 Hoffmann La Roche Composicoes farmaceuticas contendo inibidores da lipase e quitosano
HRP20010688B1 (en) 1999-03-29 2008-10-31 F. Hoffmann - La Roche Ag Glucokinase activators
GB0224084D0 (en) * 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
US20060052597A1 (en) * 2002-10-22 2006-03-09 Best Desmond J Aryloxyalkylamine derivatives as h3 receptor ligands
CA2569611C (en) * 2004-06-21 2012-12-11 F. Hoffmann-La Roche Ag Indole derivatives as histamine receptor antagonists
EP1968967B1 (en) * 2005-11-30 2011-04-27 F. Hoffmann-La Roche AG 1,1-dioxo-thiomorpholinyl indolyl methanone derivatives for use as h3 modulators
US7507736B2 (en) * 2007-02-07 2009-03-24 Hoffmann-La Roche Inc. Indol-2-yl-piperazin-1-yl-methanone derivatives

Also Published As

Publication number Publication date
TW200804340A (en) 2008-01-16
JP2009517433A (ja) 2009-04-30
CN101316840A (zh) 2008-12-03
CN101316840B (zh) 2012-08-08
AU2006319234B2 (en) 2012-01-19
US20070123515A1 (en) 2007-05-31
AR057989A1 (es) 2008-01-09
KR101124156B1 (ko) 2012-03-23
US7745479B2 (en) 2010-06-29
JP4879997B2 (ja) 2012-02-22
CA2630314A1 (en) 2007-06-07
EP1957479A2 (en) 2008-08-20
WO2007062999A3 (en) 2007-07-26
WO2007062999A2 (en) 2007-06-07
EP1957479B1 (en) 2011-03-02
TWI333490B (en) 2010-11-21
IL191314A (en) 2012-06-28
BRPI0619268A2 (pt) 2011-09-20
ATE500244T1 (de) 2011-03-15
KR20080076980A (ko) 2008-08-20
DE602006020482D1 (de) 2011-04-14
RU2008126391A (ru) 2010-01-10
ES2359739T3 (es) 2011-05-26
ZA200804301B (en) 2009-04-29
AU2006319234A1 (en) 2007-06-07

Similar Documents

Publication Publication Date Title
NO20082136L (no) 1,5-substituerte indol-2-yl-amidderivater
NO20082096L (no) Azaindol-2-karboksamidderivativer
NO20083058L (no) Cykloheksylsulfonamidderivater med H3 reseptor aktivitet
NO20082939L (no) Sykloheksyl piperasinyl metanon derivater og anvendelse av disse som histamin H3 reseptor modulatorer
NO20075082L (no) Pyridin-3-karboksamidderivater som CB1-inversagonister
NO20070336L (no) Indolderivater som histamin-reseptorantagonister
IL189191A0 (en) Thiazolyl piperidine derivatives useful as h3 receptor modulators
WO2008040649A3 (en) Pyrazine-2-carboxamide derivatives as cb2 receptor modulators
NO20072608L (no) Biaryloksymetylarenkarboksylsyrer
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
NO20082214L (no) 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer
CY1111733T1 (el) Παραγωγα 2-(1η-ινδολυλοσουλφανυλ)-βενζυλαμινης ως ssri
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
MX2010002938A (es) Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
NO20080394L (no) N-(arylalkyl)-1H-pyrrolopyridin-2-karboksamidderivater, fremstilling og anvendelse derav
WO2006100081A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
ATE466854T1 (de) 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
NO20080553L (no) Azinyl-3-sulfonylindazolderivater som 5-hydroksytrypyamin-6 ligander
MX2007011698A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
NO20080937L (no) Substituerte-3-sulfonylindazolderivater som 5-hydroksytryptamin-6-ligander
NO20075209L (no) Substituerte aryl 1,4-pyrazinderivater
DE602006010540D1 (de) (3,4-dihydro-chinazolin-2-yl)-(2-aryloxy-ethyl)-amine mit aktivität am 5-ht-rezeptor
TW200637817A (en) 5-aminoindole derivatives

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application